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We measured the antibody response in 10 victims of acute blunt trauma and penetrating trauma
who were immunized against Klebsiella pneumoniae and Pseudomonas species within 72 hours of
injury. The two vaccines, which were previously shown to be safe and immunogenic in uninjured
humans, were a 24-valent K. pneumoniae capsular polysaccharide vaccine and an eight-valent
Pseudomonas a-polysaccharide-toxin A conjugate vaccine. The patients were between 18 and 44
years of age, had Injury Severity Scores that ranged between 9 and 34, and did not have chronic
infections or malignancies. On days 14 and 28 after immunization, all patients had a response of
greater than fourfold to at least six of the nine Pseudomonas vaccine antigens. Half of the patients
responded to eight of the nine antigens. Nine patients responded to at least 18 of 24 Klebsiella
antigens, and seven patients responded to 22 of the 24 antigens. No important side effects were
attributed to the vaccines. The results of this preliminary study indicate that active immunization
against potential pathogens is possible in victims of acute trauma.
The victim of serious trauma is predisposed to infection
with gram-negative bacteria. Infections with these organisms
increase the likelihood ofmultiple organ dysfunction and death.
The more severe the trauma, the greater the risk for infection
and organ dysfunction [I]. Multiple immunologic alterations
have been described in persons who have been injured, and
these alterations may predispose to the development of infec-
tions [1]. These immunologic alterations have not been well
controlled with use of current therapies. If active immunization
raises the titers of protective antibodies to specific pathogens
and results in protection against infection with those pathogens,
immunization of injured civilians or potentially injured soldiers
would be valuable. We evaluated two vaccines that have proved
safe and immunogenic in >2,000 volunteers [2].
Methods
Patients who were selected had been admitted to the R. A.
Cowley Shock Trauma Center (Baltimore) and were considered
evaluable if they were <45 years of age; had sustained acute
blunt or penetrating trauma with an Injury Severity Score (ISS)
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[3] of ~9 within the previous 48 hours; had no known chronic
infections, malignancies, or autoimmune diseases; and pro-
vided informed consent. Blood samples were obtained to deter-
mine preimmunization antibody concentrations. Following
phlebotomy, 1,200 J1g of the polyvalent Klebsiella capsular
polysaccharide vaccine (Klebvax) was injected deeply into the
right deltoid muscle, and 200 J1g of Pseudomas O-polysaccha-
ride-toxin A (Nosovac) conjugate vaccine was injected into the
left deltoid muscle. The vaccines, which were manufactured
and supplied by the Swiss Serum and Vaccine Institute in
Berne, Switzerland, and are described in detail by Edelman et
a1. [4] had been previously shown to be safe and effective
[2, 4]. The vaccines were lyophilized and reconstituted prior
to use.
Following the injection, patients were observed for 1 hour
for any acute adverse reactions, and the vaccination sites were
examined over a 48-hour period for local reaction. Phlebotomy
was performed ~ 14 days and 28 days after vaccination to
measure antibody response to the vaccine components. All
blood samples were frozen at -70°C until they were assayed.
Serum IgG antibody concentrations were measured for each
of the 33 vaccine antigens (24 Klebsiella antigens and nine
Pseudomonas antigens [8 Pseudomonas and toxin A]) by a
previously described ELISA [4].
Results
Thirteen patients gave informed consent for the study; one
patient later declined participation, and two did not return for
postimmunization phlebotomy. The ages of the patients ranged
from 18 to 43 years, 70% were male, and half had sustained
blunt trauma. None ofthe patients had undergone splenectomy.
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Table 1. Geometric mean IgG antibody responses among 10 patients who received eight-valent Pseudomonas O-polysaccharide-toxin A
conjugate vaccine.
Antibody concentrations Antibody concentrations Percentage of patients with
Preimmunization on day 14 after on day 28 after at least a fourfold rise in
antibody concentrations immunization immunization antibody concentrations
Antigen (JLglmL ± SD)* (JLglmL ± SD)* (J-lglmL ± SD)* after immunization
IT-I 11.7 ± 2.2 28.3 ± 2.2 187.2 ± 2.7 100
IT-2 48.8 ± 1.7 267.1 ± 2.0 247.4 ± 2.1 70
IT-3 7.24 ± 1.9 43.6 ± 1.8 36.4 ± 2.1 70
IT-4 14.1 ± 1.5 141.2 ± 1.6 103.9 ± 1.8 100
IT-5 7.8 ± 1.7 87.5 ± 2.2 62.1 ± 2.5 80
IT-7 5.6 ± 2.1 38.3 ± 2.3 43.2 ± 2.3 90
Habs3 18.9 ± 2.0 110.8 ± 2.7 112.2 ± 2.8 60
Habs4 18.1 ± 1.8 299.7 ± 2.3 228.5 ± 2.6 100
Toxin A 1.36 ± 1.5 10.1 ± 3.5 9.85 ± 3.0 90
* Only nine samples were obtained on days 14 and 28.
ISS scores ranged from 9 to 34 (mean score, 18). Seven of 10
patients were enrolled within 48 hours of injury. Three patients
received the vaccines between 52 and 62 hours after injury.
None ofthe patients enrolled in the study died. One patient
failed to return for phlebotomy on day 14; therefore, nine
postimmunization specimens were collected around day 14
(range of collection times, days 11-17). One patient failed
to return for phlebotomy on day 28; therefore, nine speci-
mens were collected around day 28 (range of collection
times, days 24-40). The geometric mean antibody concen-
tration (GMAC) in serum before immunization and at day
14 and day 28 following immunization was determined for
24 components of the Klebsiella vaccine and nine compo-
nents (eight polysaccharide antigens and toxin A) of the
Pseudomonas vaccine.
Antibody response. All patients responded with a greater
than fourfold rise in GMAC to six or more of the nine antigens
in the Pseudomonas vaccine (table 1). Half of the patients
responded to eight of the nine antigens. All patients responded
to IT-I, IT-3, and H4. In only two cases, a response to an
individual antigen that was not present on day 14 was present
on day 28.
All patients but one responded to at least 18 of the 24 anti-
gens in the Klebsiella capsular polysaccharide with a greater
than fourfold rise in GMAC (table 2). Seven of the 10 patients
responded to 22 of the 24 antigens. In only three cases, a
response to an individual antigen that was not present on day
14 was present on day 28. One antigen, K35, was poorly immu-
nogenic (only 5 of 10 patients responded). Antibody response
to this antigen has also been weak in uninjured humans [4].
Tetanus toxoid. Five of the ten patients received tetanus
toxoid within 24 hours of admission. All patients confirmed to
have received the tetanus vaccine had greater than fourfold
increases in serum IgG antibody levels. A sixth patient, who
had no record of having previously received tetanus toxoid,
had a greater than 20-fold increase in IgG antibody to tetanus.
This magnitude of response is consistent with that of the five
other tetanus vaccine recipients. This patient may have received
tetanus toxoid that had not been documented in the medical
record. The other four patients who did not receive tetanus
toxoid had no significant increase in antibody titer.
Adverse reactions. None of the patients had acute systemic
reactions to the vaccines. Three patients developed low-grade
fevers (temperatures ranged from 99.l°P to 101°F) within 48
hours of vaccination. Only one patient had a local reaction to
the Pseudomonas vaccine, with some mild tenderness at the
injection site 24 hours after injection. There were no vaccine-
related abnormalities of liver enzyme levels.
Discussion
During the 1980s, Pseudomonas aeruginosa accounted for
10% of infections and Klebsiella pneumoniae accounted for
9% of infections at our trauma center [1]. In this preliminary
study, we have demonstrated that patients who have sustained
moderate injuries (mean ISS score, 18) can be actively immu-
nized with a polyvalent Klebsiella capsular polysaccharide vac-
cine and a Pseudomonas O-polysaccharide-toxin A conjugate
vaccine. All patients immunized with the Pseudomonas conju-
gate vaccine had a greater than fourfold elevation in titers of
antibodies to a minimum of six of the nine antigens. Ninety
percent of the patients vaccinated with the Klebsiella polysac-
charide vaccine had a greater than fourfold rise in antibody
concentrations to at least 18 of the 24 antigens. It was not
apparent that the immunologic responses of these patients were
diminished by the type of injury or the severity of injury or
by the receipt of homologous blood transfusions prior to immu-
nization (three patients had received ;:::2 units of blood).
We measured the responses on days 14 and 28, as was done
in previous studies with volunteers [4]. An antibody response
was manifest by day 14 in almost all cases. However, patients
who have been injured are at risk for developing gram-negative
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Table 2. Geometric mean IgG antibody responses among 10 patients who received 24-valent Klebsiella capsular polysaccharide vaccine.
Antibody concentrations Antibody concentrations Percentage of patients with
Preimmunization on day 14 after on day 28 after at least a fourfold rise in
antibody concentrations immunization immunization antibody concentrations
Antigen (t-tg/mL ± SD)* (t-tg/mL ± SD)* (t-tg/mL ± SD)* with immunization
K2 2.3 ± 2.1 60.3 ± 4.6 31.6 ± 4.6 80
K3 1.5 ± 1.4 10.0 ± 2.9 7.2 ± 2.9 70
K5 4.3 ± 1.8 67.6 ± 3.7 40.7 ± 5.4 80
K9 1.6 ± 1.4 19.5 ± 3.1 12.3 ± 2.4 80
K10 1.3 ± 1.4 24.0 ± 2.3 26.9 ± 3.5 100
K15 2.6 ± 2.5 57.5 ± 2.5 40.7 ± 2.8 100
K16 1.2 ± 1.5 28.2 ± 4.6 22.9 ± 2.2 90
K17 3.2 ± 2.3 27.5 ± 3.4 20.4 ± 2.7 100
K18 1.9 ± 2.5 31.6 ± 3.5 30.8 ± 2.8 100
K21 2.45 ± 3.0 19.1 ± 2.2 12.3 ± 2.1 90
K22 2.7 ± 3.0 23.4 ± 2.1 16.6 ± 2.5 80
K25 2.9 ± 2.3 40.7 ± 2.9 26.3 ± 3.5 90
K28 4.9 ± 2.0 77.6 ± 3.7 46.8 ± 4.3 80
K30 1.6 ± 2.2 4.27 ± 2.9 15.5 ± 3.2 90
K35 4.4 ± 1.9 22.4 ± 3.5 19.1 ± 3.5 50
K43 2.8 ± 2.4 36.3 ± 4.3 12.6 ± 3.2 70
K52 1.9 ± 2.1 17.4 ± 3.1 23.4 ± 2.7 90
K53 4.1 ± 2.8 8.5 ± 4.0 46.8 ± 4.4 90
K55 2.1 ± 1.6 45.7 ± 4.1 28.8 ± 4.4 90
K60 2.2 ± 3.0 4.90 ± 4.1 25.7 ± 4.8 90
K61 1.8 ± 2.1 46.9 ± 2.9 47.9 ± 2.9 90
K62 2.3 ± 1.7 29.5 ± 3.6 21.4 ± 3.8 90
K63 1.l±1.2 29.5 ± 3.6 21.4 ± 3.8 90
K64 2.9 ± 2.8 25.7 ± 4.3 24.0 ± 3.9 80
* Only nine samples were obtained on days 14 and 28.
infections early following the injury; hence, the rapidity of
antibody response after immunization may be crucial.
In animal models, antibodies to the capsular polysaccharide
ofKlebsiella have provided significant protection against death
due to infection with Klebsiella species. Likewise, antibodies
to products of P. aeruginosa have been protective in mice [2].
To determine if this mode of immune enhancement is effective
in preventing infections due to Klebsiella species and P. aerugi-
nosa in trauma victims, it must now be determined whether an
adequate antibody response occurs in more seriously injured
patients and whether it occurs earlier after immunization. In
subsequent studies, both IgG and IgM antibody concentrations
should be measured, and the possible immunosuppressive ef-
fect of homologous blood transfusions should be considered.
If active immunization is effective in quickly generating levels
of antibodies that are protective, its safety and economy make
it an attractive prophylactic technique.
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